

Notice reference number: 1164.17.10

Notice date: 23 October 2017

What's this about?

Effective date: 23 October 2017

<input checked="" type="checkbox"/> ASX Trade	<input type="checkbox"/> ASX 24	<input type="checkbox"/> ASX TECH				
<input checked="" type="checkbox"/> Trading	<input type="checkbox"/> Clearing	<input type="checkbox"/> Settlement	<input type="checkbox"/> ALC	<input type="checkbox"/> ASX NET		
<input type="checkbox"/> Operations	<input type="checkbox"/> Technology	<input type="checkbox"/> Market Data	<input type="checkbox"/> Rules	<input checked="" type="checkbox"/> Compliance	<input type="checkbox"/> Risk	<input checked="" type="checkbox"/> Other

Title

CannPal Animal Therapeutics Limited – Admission and Commencement of Official Quotation

Description

CannPal Animal Therapeutics Limited (Company) was admitted to the official list of ASX Limited (ASX) on 23 October 2017.

Official quotation of the Company's shares will commence at 11:00 am AEDT on 25 October 2017. The Company has raised \$6,000,000 pursuant to the offer under a prospectus dated 28 August 2017 by the issue of 30,000,000 fully paid ordinary shares at an issue price of \$0.20 per share.

<u>Quoted Securities:</u>	37,549,997 fully paid ordinary shares
<u>ASX Code:</u>	CP1
<u>Time:</u>	11:00 am AEDT
<u>Date:</u>	25 October 2017
<u>ASX Trade Abbreviation:</u>	CANNPAL
<u>ISIN:</u>	AU000000CP17
<u>Home Branch:</u>	Perth
<u>Industry Classification:</u>	TBA
<u>Registered Office:</u>	Level 3, 45a Bay Street, DOUBLE BAY NSW 2028 Tel: +61 2 6108 3622
<u>Company Secretary:</u>	Baden Bowen
<u>Share Registry:</u>	Computershare Investor Services Pty Limited Level 11, 172 St Georges Terrace PERTH WA 6000
<u>Balance Date:</u>	30 June

<u>CHES:</u>	Participating. The Company will also operate an issuer sponsored subregister.
<u>Place of Incorporation:</u>	Australian Capital Territory
<u>Dividend Policy:</u>	See page 21 of the Company's prospectus dated 28 August 2017.
<u>Activities:</u>	Research, development and commercialisation of cannabinoid derived medicines for animal health.
<u>ASX Restricted Securities:</u>	<p>49,365,405 fully paid ordinary shares to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>2,000,000 unquoted options exercisable at \$0.25 each on or before 1 June 2020 to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>1,500,000 unquoted options exercisable at \$0.25 each on or before 26 September 2020 to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>7,250,000 unquoted options exercisable at \$0.20 each on or before 24 March 2022 to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>625,000 Class A performance rights to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>625,000 Class B performance rights to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>625,000 Class C performance rights to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>625,000 Class D performance rights to be classified as restricted securities for a period of 24 months from the date of quotation of the Company's securities.</p> <p>5,584,598 fully paid ordinary shares to be classified as restricted securities for a period of 12 months from the date of issue, being 2 March 2017.</p> <p>1,500,000 unquoted options exercisable at \$0.25 each on or before 10 July 2020 to be classified as restricted securities for a period of 12 months from the date of issue, being 10 July 2017.</p>

What do I need to do and by when?

Instructions

For further details, please refer to the Company's prospectus dated 28 August 2017.

Need more information?

Issued by

Sebastian Bednarczyk

Contact Details

08 9224 0000

Disclaimer